Literature DB >> 18587106

Review paper: preclinical models of psoriasis.

D M Danilenko1.   

Abstract

Psoriasis is the most common autoimmune disease in man and is characterized by focal to coalescing raised cutaneous plaques with consistent scaling and variable erythema. The specific pathogenesis of psoriasis is not completely understood, but the underlying mechanisms involve a complex interplay between epidermal keratinocytes, T lymphocytes as well as other leukocytes (including dendritic cells and other antigen presenting cells [APCs]), and vascular endothelium. Mirroring the complexity of mechanisms that underlie psoriasis, there are a relatively large number of models of psoriasis. Each model is based on a slightly different pathogenic mechanism, and each has its similarities to psoriasis as well as its limitations. In general, psoriasis models can be very broadly divided on the basis of the pathogenic mechanisms that interplay to cause psoriasis, with the addition of several relatively poorly defined spontaneous murine mutant models. Other than the spontaneous mutant models, murine models of psoriasis can be divided into those that are genetically engineered (transgenic and knockout-with manipulation of either the epidermis, leukocytes, or the endothelium), and those that are induced (either by immune transfer or by xenotransplantation of skin from psoriatic patients). In addition to the murine models, in vitro human epidermal models have recently become more widely utilized. While no one single model of psoriasis is ideal, many have proven to be extremely valuable in investigating and better understanding the molecular mechanisms that underlie the complex interplay between epidermal keratinocytes, the innate and adaptive immune system, and the vascular endothelium in psoriasis.

Entities:  

Mesh:

Year:  2008        PMID: 18587106     DOI: 10.1354/vp.45-4-563

Source DB:  PubMed          Journal:  Vet Pathol        ISSN: 0300-9858            Impact factor:   2.221


  22 in total

1.  Development of paclitaxel-TyroSpheres for topical skin treatment.

Authors:  Brian E Kilfoyle; Larisa Sheihet; Zheng Zhang; Marissa Laohoo; Joachim Kohn; Bozena B Michniak-Kohn
Journal:  J Control Release       Date:  2012-06-23       Impact factor: 9.776

2.  Development of a bioengineered skin-humanized mouse model for psoriasis: dissecting epidermal-lymphocyte interacting pathways.

Authors:  Sara Guerrero-Aspizua; Marta García; Rodolfo Murillas; Luisa Retamosa; Nuria Illera; Blanca Duarte; Almudena Holguín; Susana Puig; Maria Isabel Hernández; Alvaro Meana; Jose Luis Jorcano; Fernando Larcher; Marta Carretero; Marcela Del Río
Journal:  Am J Pathol       Date:  2010-10-22       Impact factor: 4.307

Review 3.  CCR6 as a possible therapeutic target in psoriasis.

Authors:  Michael N Hedrick; Anke S Lonsdorf; Sam T Hwang; Joshua M Farber
Journal:  Expert Opin Ther Targets       Date:  2010-09       Impact factor: 6.902

Review 4.  Immune responses and therapeutic options in psoriasis.

Authors:  Inna S Afonina; Elien Van Nuffel; Rudi Beyaert
Journal:  Cell Mol Life Sci       Date:  2021-01-02       Impact factor: 9.261

Review 5.  Polymeric nanoparticles-based topical delivery systems for the treatment of dermatological diseases.

Authors:  Zheng Zhang; Pei-Chin Tsai; Tannaz Ramezanli; Bozena B Michniak-Kohn
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2013-02-05

6.  Varying phenotypes in swine versus murine transgenic models constitutively expressing the same human Sonic hedgehog transcriptional activator, K5-HGLI2 Delta N.

Authors:  Amy C McCalla-Martin; Xiaoxin Chen; Keith E Linder; Jose L Estrada; Jorge A Piedrahita
Journal:  Transgenic Res       Date:  2010-01-23       Impact factor: 2.788

7.  Screening of flavonoid "quercetin" from the rhizome of Smilax china Linn. for anti-psoriatic activity.

Authors:  A Vijayalakshmi; V Ravichandiran; Velraj Malarkodi; S Nirmala; S Jayakumari
Journal:  Asian Pac J Trop Biomed       Date:  2012-04

8.  Soy Phosphatidylglycerol Reduces Inflammation in a Contact Irritant Ear Edema Mouse Model In Vivo.

Authors:  Ding Xie; Vivek Choudhary; Mutsa Seremwe; John G Edwards; Angela Wang; Aaron C Emmons; Katherine A Bollag; Maribeth H Johnson; Wendy B Bollag
Journal:  J Pharmacol Exp Ther       Date:  2018-04-25       Impact factor: 4.030

9.  Molecular and histopathological profiling of imiquimod induced dermatosis in Swiss Wistar rats: contribution to the rat model for novel anti-psoriasis treatments.

Authors:  Ajla Smajlović; Anja Haverić; Amer Alić; Maida Hadžić; Ahmed Smajlović; Indira Mujezinović; Naida Lojo-Kadrić; Jasmin Ramić; Nikolina Elez-Burnjaković; Sanin Haverić; Lejla Pojskić
Journal:  Mol Biol Rep       Date:  2021-06-07       Impact factor: 2.316

10.  Development of a psoriatic-like skin inflammation rat model using imiquimod as an inducing agent.

Authors:  Komal M Parmar; Chetan S Jagtap; Nitin T Katare; Mahaveer Dhobi; Satyendra K Prasad
Journal:  Indian J Pharmacol       Date:  2021 Mar-Apr       Impact factor: 1.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.